Generic Name:
Dabrafenib & Trametinib in combo
Project Status:
Complete
Therapeutic Area:
Non-Small Cell Lung Cancer
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Tafinlar & Mekinist in combo
Project Line:
Reimbursement Review
Project Number:
PC0106-000
NOC Date:
Details
Strength:
Dabrafenib: 50mg and 75mg capsules; Trametinib: 0.5mg and 2.0mg tablet
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer
Funding Request:
In combination for the treatment of patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation and who have been previously treated with chemotherapy
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Novartis Pharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued: